Page 10 - Dave Ricks News Today

Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2023 Earnings Conference Call.

Eli Lilly's experimental Alzheimer's drug slowed disease progression in a large-scale study.

The success means patients and their caregivers could soon have another therapy shown to slow the disease alongside Leqembi — made by Cambridge biotech Biogen and Japanese drug maker Eisai — which was approved in January.

If approved, Donanemab has annual multi-billion-dollar sales potential. Lilly shares rose 6% in early-afternoon trading.

Eli Lilly Co. s shares climbed in premarket trading after its experimental drug for Alzheimer s slowed the progress of the disease in a final stage...

While each transaction needs to be evaluated on its own merits, the Club has come to recognize that sometimes, less is more.

LLY earnings call for the period ending March 31, 2023.

Eli Lilly (LLY) made up for a first-quarter earnings miss with a raised outlook and positive obesity-trial data for a potential blockbuster drug.

Urge your member of Congress to protect American patients and stop this price control regime.

Eli Lilly is investing an additional $1.6 billion and adding 200 new jobs at its two new manufacturing sites within LEAP Innovation Park in Boone County, Ind.